Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer.

Clark JL, Dresser K, Hsieh CC, Sabel M, Kleer CG, Khan A, Shaw LM.

Breast Cancer Res Treat. 2011 Dec;130(3):759-72. doi: 10.1007/s10549-011-1353-1. Epub 2011 Jan 22.

2.

[Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].

Zhang B, Liu FF, Ma YJ, Gu F.

Zhonghua Zhong Liu Za Zhi. 2013 Dec;35(12):904-9. Chinese.

PMID:
24506959
3.

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV.

Breast Cancer Res Treat. 2010 Oct;123(3):651-60. doi: 10.1007/s10549-009-0632-6. Epub 2009 Nov 19.

4.

[Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].

Ma XM, Han YW, Zhang J, Cui WJ, Wang X.

Zhonghua Zhong Liu Za Zhi. 2013 May;35(5):372-6. doi: 10.3760/cma.j.issn.0253-3766.2013.05.011. Chinese.

PMID:
24054015
5.
6.

Expression of nuclear insulin receptor substrate 1 in breast cancer.

Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S, Surmacz E.

J Clin Pathol. 2007 Jun;60(6):633-41. Epub 2006 Aug 1.

7.

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.

Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, Bander NH, Shin SJ.

APMIS. 2014 Jun;122(6):482-9. doi: 10.1111/apm.12195. Epub 2013 Dec 5.

PMID:
24304465
8.

Morphological profile and receptor status in breast carcinoma: an institutional study.

Rao C, Shetty J, Kishan Prasad HL.

J Cancer Res Ther. 2013 Jan-Mar;9(1):44-9. doi: 10.4103/0973-1482.110358.

9.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

10.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

11.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
12.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
13.

Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.

Serrero G, Hawkins DM, Yue B, Ioffe O, Bejarano P, Phillips JT, Head JF, Elliott RL, Tkaczuk KR, Godwin AK, Weaver J, Kim WE.

Breast Cancer Res. 2012 Feb 8;14(1):R26.

14.

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.

Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12.

PMID:
21837481
15.

Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?

Jones T, Neboori H, Wu H, Yang Q, Haffty BG, Evans S, Higgins S, Moran MS.

Ann Surg Oncol. 2013 Sep;20(9):2866-72. doi: 10.1245/s10434-013-2994-6. Epub 2013 May 10.

PMID:
23661183
16.

Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.

Francis G, Beadle G, Thomas S, Mengersen K, Stein S.

Pathology. 2006 Oct;38(5):391-8.

PMID:
17008275
17.

Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.

Gokce H, Durak MG, Akin MM, Canda T, Balci P, Ellidokuz H, Demirkan B, Gorken IB, Sevinc AI, Kocdor MA, Saydam S, Harmancioglu O.

Breast J. 2013 Jul-Aug;19(4):374-81. doi: 10.1111/tbj.12128. Epub 2013 May 29.

PMID:
23714006
18.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
19.

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Tang D, Xu S, Zhang Q, Zhao W.

Med Oncol. 2012 Jun;29(2):526-33. doi: 10.1007/s12032-011-9948-2. Epub 2011 Apr 26.

PMID:
21519872
20.

CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.

Pathol Res Pract. 2006;202(8):569-76. Epub 2006 Jul 7.

PMID:
16828238
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk